Wiltshire man goes home the same day after major robotic cancer surgery
A cancer patient returned home the same day after undergoing major surgery.
Eddie Harvey, 67, underwent a successful robotic radical prostatectomy at the Royal United Hospitals (RUH) Bath NHS Foundation Trust.
He returned to his Corsham home on the same day, only the second RUH patient to have this type of surgery and make it home in the same day.
The Da Vinci surgical robot was used to perform the operation.
Read more: Wiltshire man to be sentenced for Devizes attempted murder
The robot was funded by RUH's charity, RUHX.
It allows surgeons to perform complex procedures with precision and minimal access.
Mr Harvey said: "I was referred to the RUH by my GP after a check-up, and an MRI scan at the hospital showed there was suspicion of cancer in my prostate.
"I then had prostate biopsies which confirmed it.
"Within a couple of weeks I was having the surgery.
"Everything moved really quickly, I was so impressed.
"I arrived at hospital at 7am on the morning of the operation and was back home later that night.
"I was a bit surprised but delighted that I could be back home in my own bed that same day.
"There was no pressure on me to go home that day, but I felt good and had complete trust in the surgeon who I knew wouldn't have let me leave if he didn't think I was ready to.
"I know that being discharged on the same day for this kind of surgery isn't going to be possible for everyone, but for those who are eligible it's fantastic."
The surgery was led by consultant urological and robotic surgeon Ayman Ali.
He said: "This really is a fantastic achievement for the RUH and will hopefully be the start of many similar operations where patients can now return home the same day.
"This is now possible due to the use of the robot, which provides better precision and accuracy which also enhances recovery times too.
Read more: Bid to save beloved £750k Chippenham farm falls short
"While same day discharge will not be suitable for all patients, we know that being at home can aid patient recovery and lead to better outcomes for the people we care for.
"I would like to say a huge thank you to our dedicated surgical and anaesthetic team, nursing staff in our Day Surgery Unit, and urology specialist nurses who have made this milestone possible.
"This accomplishment is a testament to our shared commitment to innovation and delivering exceptional patient-centred care."
The surgical robot is now used in a range of surgeries at the RUH, including gynaecology oncology and colorectal operations.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
6 hours ago
- Medscape
MRI-Led Surveillance Stratifies Prostate Cancer Risk
In a cohort study of patients with prostate cancer, MRI-led risk-adapted active surveillance demonstrated effectiveness in risk stratification. The approach showed that MRI visibility and the presence of secondary Gleason pattern 4 at baseline were associated with higher rates of progression and treatment initiation. METHODOLOGY: Researchers analysed 1150 patients who started active surveillance between February 2000 and July 2023, including those with a Gleason score (GS) ≤ 3 + 4, prostate-specific antigen (PSA) < 20 ng/mL, and at least two MRI scans. Participants underwent PSA testing three to four times in the first year, followed by biannual testing; MRI was performed at baseline and 12 months, with an additional MRI scan performed at 24 months for those with MRI-visible lesions at baseline. Patients were stratified into four groups on the basis of baseline risk factors, including GS (3 + 3 vs 3 + 4) and MRI visibility ("non-visible disease" vs "visible disease"). The primary outcome was event-free survival, with an event defined as the detection of GS ≥ 4 + 3 or the initiation of any prostate cancer treatment. The median follow-up duration was 64 months per person overall and 72 months for 732 patients without an event. At baseline, 64% of patients had GS 3 + 3 and 36% had GS 3 + 4; 49% of those with GS 3 + 4 had MRI-visible disease. TAKEAWAY: Event-free survival rates varied significantly on the basis of the risk group, with 5-year rates of 91% for non-visible GS 3 + 3, 71% for MRI-visible GS 3 + 3, 71% for non-visible GS 3 + 4, and 44% for MRI-visible GS 3 + 4 disease. Among 487 patients who underwent follow-up biopsies, histological upgrade to GS ≥ 4 + 3 occurred in 67 patients; non-visible GS 3 + 3 cases had 5- and 10-year rates of 1.2% and 6.1%, respectively, for histological progression to GS ≥ 4 + 3, while the rates were 17% and 43% for those with MRI-visible GS 3 + 4 disease at baseline, respectively. Progression to nodal or bone metastases was observed in 10 patients, occurring only in those who had declined recommended follow-up MRI and/or biopsies. The 10-year rate of commencing treatment was 28% for those with non-visible GS 3 + 3 disease vs 85% for those with MRI-visible GS 3 + 4 disease and 46% for those with non-visible GS 3 + 4 disease vs 54% for those with MRI-visible GS 3 + 3 disease. IN PRACTICE: "Results from our cohort suggest that AS [active surveillance] patients can be monitored safely with MRI, and the decision to biopsy was based on MRI findings and PSA changes. Prospective, multicentre, clinical trials are required and currently being designed to further evaluate this approach," the authors wrote. SOURCE: This study was led by Cameron Englman, Division of Surgery & Interventional Science, University College London, London, England. It was published online on May 27, 2025, in European Urology . LIMITATIONS: Compared with time-based biopsy protocols, the MRI-led risk-adapted approach may underestimate histological progression. Additionally, as a cohort study without a strict protocol, practice evolved alongside contemporary pathology and radiology standards, with MRI quality, reporting standards, and the definition of radiological progression varying over time, particularly improving after the adoption of the PRECISE recommendations in 2016. DISCLOSURES: This study did not receive any specific funding. Several authors reported receiving consulting fees and grants and having other ties with various sources.
Medscape
6 hours ago
- Medscape
Radiology Workforce Shortages Impacting Cancer Care
A chronic shortage of radiologists and oncologists is putting patients in the UK at risk, a new report found. The annual workforce census by the Royal College of Radiologists (RCR) warned that the safe delivery of NHS cancer care is becoming 'increasingly impossible' due to an escalating shortfall of doctors coupled with rising demand for care. In 2024, the UK had a 29% shortfall of clinical radiologists, with regional gaps ranging from 25% in Scotland to 32% in Wales. The workforce grew by 4.7% that year — less than in 2023, when it increased by 6.3%. The college forecasts the radiologist shortfall will reach 39% by 2029. Oncology Under Strain Clinical oncologists are also in short supply, with a current 15% gap expected to rise to 19% by 2029. This is despite a 5.4% increase in the workforce in 2024—the strongest growth since 2018. The RCR reported that 23% of cancer centres were experiencing recruitment freezes, making it harder to meet growing demand. Demand Continues to Outpace Capacity The shortages threaten the government's plans to cut waiting times and improve cancer outcomes. In 2024, demand for computerised tomography (CT) and magnetic resonance imaging (MRI) grew by 8%, but workforce growth did not keep pace. Every radiology leader surveyed last year reported delays to diagnostic scans caused by staff shortages. Nine in 10 radiology team leaders reported that patients were waiting longer to start treatment, while seven in 10 expressed concern that staff shortages were putting patient safety at risk – down slightly from 85% in 2023. Chronic problems such as workforce shortages, reporting backlogs, and staff vacancies remain too high, according to Dr Robin Proctor, the RCR's m edical director responsible for professional practice and clinical radiology. Consultants Leaving Earlier Staff retention is worsening, with experienced consultants leaving the NHS at younger ages. In 2024, the median age of consultant clinical radiologists leaving the NHS workforce was 50 – down from 56 in 2020. Four in five (79%) of leavers were under 60, and two in five (42%) were under 45. Clinical oncologists followed a similar trend. Their median exit age dropped to 54, from 57 in 2023 and 59 in 2022. Nearly 76% of leavers were under 60, and 26% were under 45. One consultant clinical oncologist told the college that delays in scans and treatment were resulting in missed or late cancer diagnoses. Some patients' conditions were deteriorating or reaching a stage where treatment was no longer possible. Changing Work Practices 'Working conditions and ways of working need to change if we are to address this problem and meet the growing demand for our expertise,' Proctor said. The RCR has called on the government to invest in training and recruitment. In 2024, the NHS spent an estimated £325 million on temporary radiology staff. The cost of outsourcing had doubled since before the COVID-19 pandemic and had surged by almost a quarter in the past year. The RCR estimated that increasing radiology trainee numbers by 50% could eliminate three-quarters of the current shortfall and save the NHS £460 million over the next 10 years. 'Patients are being failed by a chronic lack of radiologists and oncologists,' said RCR president Dr Katharine Halliday. 'The longer we delay action, the worse it gets,' she added.
Yahoo
16 hours ago
- Yahoo
WVU Medicine Princeton Community Hospital breaks ground on PCH Bluefield campus
BLUEFIELD, WV (WVNS) – WVU Medicine continues to expand with the breaking of ground for the new Bluefield campus of Princeton Community Hospital. Located on Southview Drive, the $25 million facility will offer state-of-the-art care to residents in the area. The location will be home to the Bluefield Emergency Department and PCH Behavioral Health Center, and the expansion itself is part of an effort by WVU Medicine to offer comprehensive access and care to patients no matter where they are in the state, according to Princeton Community Hospital President and CEO, Karen Bowling.'One reason WVU Medicine has expanded is we want to make sure we are serving the entire community and that it is a comprehensive level of care,' she said. 'If you think about it, we're on the same medical record. Whether you're in Princeton or you're in Bluefield, whether you need to go to Ruby to have a bone marrow transplant – we're all on the same medical record.'Bowling said the expansion is about communities, families, and serving the region as well as the state. 'As someone who grew up in this region, I know firsthand how much this investment means,' she continued. 'This project is about more than bricks and mortar; it's about giving our families, friends, and neighbors access to the kind of care they deserve, right here at home. WVU Medicine is making a promise to this region, and I'm proud to be part of delivering on that promise.' WVU Medicine President & CEO, Albert Wright reiterated the importance of widespread coverage under a single umbrella as it pertains to patient care. 'This project exemplifies WVU Medicine's unwavering investment in delivering high-quality, accessible care to West Virginians,' he said. 'By expanding services and upgrading facilities, like here at the Bluefield Campus, we're not only enhancing patient care, but we're also reinforcing our long-term commitment to advancing health outcomes in southern West Virginia.'Features of the Bluefield campus will include: The new emergency department (ED) will include: 20 exam rooms, including two rooms designed for psychiatric intake Two resuscitation rooms and two triage rooms OB-ready and trauma rooms Centralized care team support stations Dedicated patient and ambulance entrances Diagnostic Radiology — two radiology rooms Computed Tomography (CT) — one CT scanner Magnetic Resonance Imaging (MRI) — one MRI scanner (a new service for Bluefield) Ultrasound — two ultrasound rooms (a new service for Bluefield) Guest speakers and live music were part of the groundbreaking celebration as guests got their first look at plans for the new facility. PCH plans to officially open the doors to its Bluefield campus in the Fall of 2027, as the provider hopes to further extend the scope of patient accessibility and care. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
